Intravenous meropenem stability in physiological saline at room temperature

European Journal of Hospital Pharmacy

Volumn 21, Issue 4, 2014, Pages 202-207

  Mollá Cantavella, Sara ^a   Ferriols Lisart, Rafael ^b   Torrecilla Junyent, Teresa ^b   Alós Almiñana, Manuel ^b  

^a Castellon University General Hospital   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; MEROPENEM; SODIUM CHLORIDE;

ACCURACY; ARTICLE; CLINICAL PRACTICE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PH MEASUREMENT; ROOM TEMPERATURE; ANALYTIC METHOD; CALIBRATION; ORGANOLEPTIC PROPERTY; PH; VALIDATION PROCESS;

EID: 84904600359     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2013-000430     Document Type: Article

References (27)

1. Meropenem Hospira 1 g polvo para solución inyectable y pefusión. Hospital UK Limited. Ficha técnica o resumen de las características del producto. Ministerio de Sanidad, Política Social e Igualdad. Aggencia Española del Medicamento y Productos Sanitarios. http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar
2. Chiara A, Andrea N. Pharmacokinetic and pharmacodynamic parameters of antimicrobials. Clin Pharmacokinet 2009;48:517-28.
3. Novelli A, Fallani S, Cassetta ML, et al. Postantibiotic leukocyte enhancement of meropenem against Gram-positive and Gram-negative strains. Antimicron Agents Chemother 2000;44:3174-6.
4. Chytra I, Stepan M, Benes J, et al. Cinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012;16:R113.
5. Taccone F. Continuous infusion of meropenem in critically ill patients: practical considerations. Crit Care 2012;16:444.
6. Smith D, Bauer S, Nicolau D. Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. Am J Health-Syst Pharm 2004;61:1682-5.
7. Berthoin K, Le Duff C, Marchand-Brynaert M, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010;65:1073-5.
8. Grant E, Zhong M, Ambrose P, et al. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health-Syst Pharm 2000;57:992-5.
9. Krämer I. Stability of meropenem in elastomeric portable infusion devices. EHP 1997;3:168-71.
10. Walker S, Varrin S, Yannicelli D, et al. Stability of meropenem in saine and dextrose solutions and compatibility with potassium chloride. Can J Hosp Pharm 1998;51:156-68.
11. McWhinney BC, Wallis SC, Hillister T, et al. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B 2010;878:2039-43.
12. ICH Topic Q 2 (R1) Validation of analytical procedures: text and methodology. June 1995 CPMP/ICH/381/95 European Medicinal Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf
13. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J 2007;9:E109-14.
14. Abdul-Aziz M, Staatz C, Kirkpatrick C, et al. Continuous infusion vs. bolus dosing: implications for beta-lactams antibiotics. Minerva Anestesiol 2012;78:94-104.
15. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142-50.
16. Lorente L, Lorenzo L, Martín M, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40:219-23.
17. Dulhunty J, Roberts J, Davis J. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infec Dis 2013;56:236-44.
18. Sakka S, Glauner A, Bulitta J, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51:3304-10.
19. Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009;33:290-1.
20. Falagas M, Giannoula S, Tansarli G, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/ tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013;56:272-82.
21. Dulhunty JM, Roberts JA, Davis JS, et al. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resusc 2013;15:179-85.
22. William A, Allison E, Jerod L, et al. Continuous-infusion antipseudomonal beta-lactam therapy in patients with cystic fibrosis. P&T 2011;36:723-63.
23. Keel R, Sutherland C, Crandon J. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents 2011;37:184-5.
24. Kuti J, Nightingale C, Knauft F, et al. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004;26:493-501.
25. Mendez A, Dalomo J, Steppe M, et al. Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample. J Pharm Biomed Analysis 2006;41:1363-6.
26. Mendez A, Chagastelles P, Palma E, et al. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Int J Pharm 2008: 95-102.
27. Mendez A, Weisheimer V, Oppe T, et al. Microbiological assay for the determination of meropenem in pharmaceutical dosage form. J Pharma Biomed Anal 2005;37:649-53.